Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroid Nodules, and Thyroid Cancer

Thyroid disorders encompass a spectrum of conditions affecting thyroid hormone production, thyroid gland structure, or both. These disorders represent some of the most common endocrine conditions encountered in clinical practice.

Hypothyroidism is defined as the deficiency of thyroid hormone, affecting almost all body systems with clinical presentations ranging from asymptomatic to life-threatening [3]. The most common cause worldwide is chronic autoimmune thyroiditis (Hashimoto's thyroiditis), though other causes include medications (amiodarone, lithium, immune checkpoint inhibitors), radioactive iodine treatment, and thyroid surgery [3].

Hyperthyroidism is characterized by suppressed thyrotropin (TSH) and elevated triiodothyronine (T3) and/or free thyroxine (FT4) concentrations. [HIGH_YIELD] Overt hyperthyroidism affects approximately 0.2% to 1.4% of people worldwide, while subclinical hyperthyroidism (low TSH with normal T3 and FT4) affects 0.7% to 1.4% globally [1]. Graves disease is the most common cause, with a prevalence of 2% in women and 0.5% in men [1].

Thyroid nodules are extremely common, usually asymptomatic findings that pose minimal risk to most patients [4]. However, 10-15% prove malignant, necessitating systematic diagnostic evaluation [4]. The past 30 years have witnessed a substantial rise in thyroid nodule detection, largely due to incidental findings on imaging studies [6].

Thyroid cancer represents the malignant transformation of thyroid tissue. Recent advances have transformed diagnostic and management approaches, with new ultrasound-based risk stratification systems and less invasive treatment options being developed [2]. [KEY_CONCEPT] The increased detection of thyroid cancer has had minimal impact on mortality rates, suggesting that historical approaches may have included unnecessary or excessive care [6].

Hypothyroidism Clinical Features

Classic symptoms include fatigue, lethargy, weight gain, and cold intolerance, though these are non-specific and diagnosis is typically made biochemically [3]. Additional manifestations include:

• Cardiovascular: Bradycardia, diastolic hypertension, pericardial effusion
• Neurologic: Depression, cognitive impairment, peripheral neuropathy
• Dermatologic: Dry skin, coarse hair, hair loss, myxedema
• Gastrointestinal: Constipation, decreased appetite
• Reproductive: Menstrual irregularities, infertility

Hyperthyroidism Clinical Features

[CLINICAL_PEARL] Untreated hyperthyroidism can cause cardiac arrhythmias, heart failure, osteoporosis, and adverse pregnancy outcomes, and is associated with increased mortality [1]. Key manifestations include:

• Cardiovascular: Tachycardia, atrial fibrillation, systolic hypertension
• Neurologic: Anxiety, tremor, hyperreflexia, proximal muscle weakness
• Dermatologic: Warm, moist skin; fine hair; onycholysis
• Gastrointestinal: Increased appetite, diarrhea, unintentional weight loss
• Ophthalmologic: Graves' orbitopathy (in Graves disease)

Thyroid Nodule Presentation

Most thyroid nodules are asymptomatic and discovered incidentally [4]. Concerning features include:

• Rapid growth
• Hoarseness (recurrent laryngeal nerve involvement)
• Dysphagia or dyspnea (mass effect)
• Cervical lymphadenopathy

[HIGH_YIELD] The presence of a thyroid bruit suggests hyperthyroidism, while delayed deep tendon reflex relaxation is characteristic of hypothyroidism.

Thyroid Function Testing

Initial Assessment: Serum TSH is the most sensitive initial test for thyroid dysfunction. [KEY_CONCEPT] TSH levels inversely correlate with thyroid hormone activity due to negative feedback.

Diagnostic Algorithm for Thyroid Dysfunction

Serum TSH | ├─ Normal TSH (0.4-4.0 mIU/L) │ └─ Euthyroid (consider non-thyroidal illness) | ├─ Elevated TSH (>4.0 mIU/L) │ ├─ Check Free T4 │ │ ├─ Low Free T4 → Overt Hypothyroidism │ │ └─ Normal Free T4 → Subclinical Hypothyroidism │ └─ Consider: Anti-TPO antibodies | └─ Suppressed TSH (<0.4 mIU/L) ├─ Check Free T4 and T3 │ ├─ Elevated Free T4/T3 → Overt Hyperthyroidism │ └─ Normal Free T4/T3 → Subclinical Hyperthyroidism └─ Consider: TSI, RAI uptake scan

Thyroid Nodule Evaluation

Ultrasound is the principal means of initial nodule assessment and should be performed when any thyroid nodule is suspected [4]. [CLINICAL_PEARL] Fine-needle aspiration (FNA) provides cytological determination and is generally applied to nodules larger than 1-2 cm based on holistic risk assessment [4].

Ultrasound Risk Stratification Features

High-risk characteristics:

• Solid hypoechoic composition
• Irregular margins
• Microcalcifications
• Taller-than-wide shape
• Cervical lymphadenopathy

The Bethesda System provides standardized cytological terminology enhancing communication among healthcare providers [4]:

Laboratory Differential Diagnosis

[HIGH_YIELD] TSH suppression with elevated radioiodine uptake: Graves disease, toxic multinodular goiter, toxic adenoma

TSH suppression with low radioiodine uptake: Thyroiditis (subacute, lymphocytic), exogenous thyroid hormone, iodine-induced hyperthyroidism

Hypothyroidism Management

Levothyroxine is the treatment of choice for hypothyroidism. [KEY_CONCEPT] Dosing is typically 1.6 mcg/kg/day for healthy adults, with adjustments based on TSH levels after 6-8 weeks [3].

Treatment Goals:

• Overt hypothyroidism: Normalize TSH (0.4-4.0 mIU/L)
• Subclinical hypothyroidism: Consider treatment if TSH >10 mIU/L or symptoms present
• Pregnancy: Target TSH 0.1-2.5 mIU/L (first trimester)

Hyperthyroidism Management

Treatment Algorithm for Hyperthyroidism

Confirmed Hyperthyroidism | ├─ Determine Etiology (RAI uptake, TSI) │ ├─ Graves Disease │ │ ├─ Antithyroid drugs (methimazole preferred) │ │ ├─ Radioactive iodine (RAI) │ │ └─ Thyroidectomy │ │ │ ├─ Toxic Multinodular Goiter/Toxic Adenoma │ │ ├─ RAI (preferred) │ │ └─ Surgery (if RAI contraindicated) │ │ │ └─ Thyroiditis │ └─ Beta-blockers + monitoring | └─ Symptomatic Management └─ Beta-blockers for all patients initially

[HIGH_YIELD] Methimazole is preferred over propylthiouracil except in pregnancy (first trimester) and thyroid storm due to lower hepatotoxicity risk.

Radioactive Iodine Therapy

Indications: Graves disease (especially recurrent), toxic multinodular goiter, toxic adenoma Contraindications: Pregnancy, breastfeeding, severe ophthalmopathy

Thyroid Nodule Management

The past decade has witnessed an increasingly conservative approach, seeking to individualize care [6]. Benign nodules can be safely monitored with minimal or long-interval follow-up imaging [6].

Management by Risk Category:

• Benign (Bethesda II): Clinical and sonographic surveillance
• AUS/FLUS (Bethesda III): Repeat FNA or molecular testing
• Follicular neoplasm (Bethesda IV): Surgical consultation
• Suspicious/Malignant (Bethesda V-VI): Surgical resection

Thyroid Cancer Management

[CLINICAL_PEARL] Less invasive alternatives to surgery for low-risk thyroid cancer, such as active surveillance and minimally invasive interventions, are being explored [2].

Surgical Approach:

• Total thyroidectomy: Most thyroid cancers >1 cm
• Lobectomy: Selected low-risk papillary microcarcinomas
• Active surveillance: Specific low-risk papillary microcarcinomas in appropriate candidates

Post-surgical Management:

• Radioactive iodine ablation: Intermediate to high-risk cases
• TSH suppression therapy: Target TSH <0.1 mIU/L (high-risk) or 0.1-0.5 mIU/L (low-risk)
• Surveillance: Serial thyroglobulin and neck ultrasound

Hypothyroidism Complications

Myxedema Coma: Life-threatening complication with mortality rates of 20-50%. Clinical features include:

• Altered mental status
• Hypothermia
• Bradycardia and hypotension
• Hypoventilation
• Hyponatremia

[CLINICAL_PEARL] Treatment requires immediate IV levothyroxine, corticosteroids, and supportive care in intensive care setting.

Cardiovascular Complications:

• Increased risk of coronary artery disease
• Diastolic dysfunction
• Pericardial effusion
• Elevated cholesterol levels

Hyperthyroidism Complications

Thyroid Storm: Medical emergency with 10-30% mortality. Diagnostic criteria include:

• Hyperthermia (>38.5°C)
• Tachycardia >140 bpm
• Altered mental status
• Heart failure or shock
• Precipitating factor (infection, surgery, iodine exposure)

Treatment Protocol:

1. Antithyroid drugs (high-dose methimazole or PTU)
2. Iodine (1 hour after antithyroid drugs)
3. Beta-blockers
4. Corticosteroids
5. Supportive care

[HIGH_YIELD] Thyroid Eye Disease (TED): Most patients develop eye manifestations while being treated for hyperthyroidism [5]. Endocrinologists have a key role in diagnosis, initial management, and specialist referral selection [5].

TED Management Approach:

• Active phase: Corticosteroids, selenium supplementation
• Severe cases: Rituximab, orbital radiotherapy, surgical intervention
• Stable phase: Rehabilitative surgery if needed

Long-term Monitoring

Hypothyroidism Follow-up:

• Initial: TSH every 6-8 weeks until stable
• Maintenance: Annual TSH monitoring
• Dose adjustments: Wait 6-8 weeks before rechecking

Hyperthyroidism Follow-up:

• Antithyroid drugs: Monthly initially, then every 3-6 months
• Post-RAI: Monitor for hypothyroidism development
• CBC monitoring: For antithyroid drug-induced agranulocytosis

Thyroid Cancer Surveillance:

• Low-risk: Annual clinical exam, TSH, thyroglobulin
• High-risk: More frequent monitoring with neck ultrasound
• Recurrence assessment: Rising thyroglobulin, new structural disease

Drug Interactions & Special Populations

Levothyroxine Absorption: Impaired by calcium, iron, proton pump inhibitors, soy products. Take on empty stomach, 60 minutes before breakfast.

Pregnancy Considerations:

• Increase levothyroxine dose by 25-30% when pregnancy confirmed
• Use propylthiouracil in first trimester hyperthyroidism
• Avoid radioactive iodine during pregnancy and breastfeeding

Prognosis by Condition

Hypothyroidism Prognosis

Excellent prognosis with appropriate levothyroxine replacement therapy. Most patients achieve normal quality of life with proper treatment [3]. [KEY_CONCEPT] Lifelong therapy is typically required for primary hypothyroidism.

Factors affecting prognosis:

• Age at diagnosis (younger patients adapt better)
• Compliance with medication
• Presence of comorbid conditions
• Appropriate dose optimization

Hyperthyroidism Prognosis

Variable outcomes depending on underlying etiology and treatment modality:

• Graves disease: 30-50% remission rate with antithyroid drugs after 12-18 months
• Radioactive iodine: 90% cure rate, but high likelihood of subsequent hypothyroidism
• Surgery: Near 100% cure rate with appropriate surgical expertise

Thyroid Cancer Prognosis

[HIGH_YIELD] Age is the most important prognostic factor in differentiated thyroid cancer, with patients <55 years having excellent outcomes regardless of tumor characteristics.

Population Health & Screening

Screening Recommendations:

• General population: No routine screening recommended
• High-risk individuals: Consider screening every 5 years after age 35
• Pregnancy: Screen women with risk factors or clinical suspicion

High-risk populations include:

• Family history of thyroid disease
• Previous neck irradiation
• Autoimmune conditions
• Medications affecting thyroid function

Quality of Life Considerations

Patient Education Priorities:

• Importance of medication compliance
• Recognition of symptoms requiring medical attention
• Understanding of lifelong therapy needs
• Proper medication timing and administration

[CLINICAL_PEARL] Subclinical thyroid dysfunction management should be individualized based on symptoms, cardiovascular risk factors, and patient preferences rather than biochemical values alone.

Emerging Therapies & Future Directions

Novel therapeutic approaches include:

• Combination T4/T3 therapy for selected hypothyroid patients
• Minimally invasive treatments for thyroid nodules (radiofrequency ablation, ethanol injection)
• Advanced systemic therapies for refractory thyroid cancer [2]
• Personalized medicine approaches based on genetic profiling

Active surveillance protocols are being refined for low-risk papillary microcarcinomas, potentially reducing overtreatment while maintaining excellent outcomes [2].

Disparities in care remain a significant concern, requiring attention to ensure equitable access to advanced diagnostic and therapeutic options across different populations [2].